Mahmoud El Sheikh

Headed Mufid whole business both Phamra and GT and managed to apply crisis managment system . Reform of team structure and manged to focus on collection in both MOH for hold money for more than 2 years by follow up and ethical work.Encouraged business development system nad managed to filter agencies and secured potential ones and establish super relateion with them both Bells and Roofa in additionto new company Goodness care . Headed pharma department at Almufid Pharmaceuticals

• Launched Roofa Spain in Kuwaiti market with significant success
• Revitalized market presence for TRB's eye lubricant products in Kuwait and achieved triple sales of the last year.
• Attracted top-tier companies as exclusive distributor in Kuwait
• Diversified Almufid's product range through unique additions
• Collaborated with senior management to develop effective profit and loss strategies
• Streamlined sales processes by adoption reducing costs and increasing profit margins.
• Set new benchmarks by equaling annual sales in just six months.
• Led negotiations on high-value contracts with national and international clients, securing attractive deals.
• Directed the expansion into new markets, conducting thorough research.
• Managed a portfolio of key accounts, fostering strong relationships and maximising sales opportunities.
• Shaped business strategy with compelling vision and data analysis.
• Analysed current strategies for strengths and weaknesses and adjusted approaches to maintain sales trajectory.

• Managed Mustela sales and marketing activities
• Achieved a growth in sales, increasing from 8k KWD to 270k KWD within three years
• Achieved significant sales growth leading to higher company profits
• Recognized for superior marketing efforts in MENA region in 2017
• Secured market leadership for Mustela in Kuwait's baby care segment
• Led sales team towards achieving quarterly targets through strategic planning and effective resource allocation.
• Monitored competitor activity, adapting strategies to maintain competitive advantage and market leadership.
• Guided sales team through challenging negotiations, securing deals that met both client and company objectives.
• Identified and pursued new business opportunities in untapped markets, expanding company reach and influence.
• Established pricing and delivery terms based on current market trends and costs.

• Led outsourcing project for Roche in Kuwait overseeing Rocephin and Roaccutane.
• Managed high-priority projects involving Actemra(Biologic) and Xofluza(COVID 19 Treatment)
• Successfully finished huge stock inventory via extensive marketing
• Prepared launch plan for Xofluza, a novel two-tablet swine flu treatment
• Achieving growth and hitting sales targets by successfully managing the team
  Designing and implementing a strategic sales plan that expands company’s customer base and ensure it’s strong presence
• Identify emerging markets and market shifts while being fully aware of new products and competition status

• Cultivated Alfasigma XIFAXAN business in private market, achieving widespread adoption in all emergency rooms
• Expanded XIFAXAN reach, securing Kuwait Oil Company as a major client
• Achieved a sales value of $450,000 in just two years
• Achieved successful inclusion of Alfasigma's Xifaxan in nationwide MOH hospitals
• Formulated monthly, quarterly, and annual budgets for marketing initiatives
• Implemented strategies to optimize team performance
• Managed team leadership through training sessions
• Monitored competitor activity, adapting strategies to maintain competitive advantage and market leadership.
• Motivated sales staff to continuously improve strategies through competitions and personalised coaching plans.

• Report directly to MENA General Manager
• Solely established Norgine presence in Kuwait
• Executed strategy to secure new prospects and build partnerships
• Maintained records of consumer information, forecasts and documentation

Analysed market trends and customer needs to inform product development and positioning.

• Managed team of ten Medical Reps and a single supervisor
• Boosted regional revenue through effective team management
• Achieved 55% contribution to overall regional performance
• Led business expansion and introduced modern insulin such as NovoMix, Levemir, and NovoRapid
• Penetration of NovoRapid, NovoMix, and Levemir in both private sector and institutions
• Successfully launched Nordilet, securing initial order pre-registration
• Shifted product line from standard GH vials to Nordilet in the western region
• Interacted effectively within teams led by Mads Bo Larsen, Melvin Oscar, Henrick Dahle